Article

Genentech, Alcon among ‘Best Companies to Work For’

New York-Fortune magazine has named Genentech and Alcon Laboratories to its latest “100 Best Companies to Work For” list.

New York-Fortune magazine has named Genentech and Alcon Laboratories to its latest “100 Best Companies to Work For” list.

South San Francisco, CA-based Genentech, with almost 11,000 employees in the United States, is fifth in the 2008 rankings. The achievement marks the company’s 10th consecutive year on the list, a distinction that cannot be claimed by any other biotechnology company, according to Genentech.

This year marks Alcon Laboratories’ 10th consecutive time on the list, too. The company, with almost 6,000 employees in the United States, ranks 60th on the 2008 list, five spots up from last year. Alcon Laboratories noted that Fortune cited the company’s retirement program, which matches employee contributions 2.4:1, as well as its benefits package, financial compensation, and U.S. headquarters campus in Fort Worth, TX.

Fortune worked with the Great Place to Work Institute to compile the list. About 1,500 firms were contacted, and 406 participated. Two-thirds of a company’s score was based on responses from a minimum of 400 randomly selected employees to a 57-question survey of their attitudes about management’s credibility, job satisfaction, and camaraderie. The other one-third of each score was based on a company’s responses to a “culture audit” that included detailed questions about compensation and benefit programs as well as a series of open-ended questions about hiring practices, methods of internal communication, training, recognition programs, diversity efforts, and other issues.

The full list appears in the Feb. 4 issue of Fortune and is available at www.fortune.com/bestcompanies.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.